Entry Coreceptor Use and Fusion Inhibitor T20 Sensitivity of Dual-Tropic R5X4 HIV-1 in Primary Macrophage Infection
- 1 March 2008
- journal article
- basic science
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 47 (3) , 285-292
- https://doi.org/10.1097/qai.0b013e31816520f6
Abstract
Macrophages are important targets for HIV-1, and R5X4 strains play a central role in pathogenesis, especially in late-stage patients who may receive the fusion inhibitor T20 (enfuvirtide). Sensitivity to T20 varies markedly among HIV-1 strains and is influenced by viral and cellular factors that affect Env/CD4/coreceptor interactions. We addressed the relation between T20 inhibition and the pathway by which R5X4 HIV-1 infects primary macrophages, which express both coreceptors. In U87/CD4/coreceptor cells, T20 sensitivity for entry through CCR5 and CXCR4 was correlated. In macrophages, the proportion of total entry mediated by each coreceptor differed among isolates. Neither pathway was uniformly more or less sensitive to T20, however, nor did the proportion of entry mediated by each coreceptor predict T20 sensitivity. T20 sensitivity for macrophage infection overall correlated modestly with that for entry through CCR5 but not through CXCR4; however, unlike U87 cells, sensitivity of entry through CCR5 and CXCR4 was not correlated. These results suggest that strain-specific factors influence R5X4 T20 sensitivity regardless of the coreceptor used, an absence of systematic differences in efficiency by which R5X4 strains use the 2 coreceptors, and that efficiency and kinetics of interactions with CCR5 are central determinants of macrophage entry even when both pathways are utilized.Keywords
This publication has 24 references indexed in Scilit:
- CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1AIDS, 2007
- The role of the N-terminal segment of CCR5 in HIV-1 Env-mediated membrane fusion and the mechanism of virus adaptation to CCR5 lacking this segmentRetrovirology, 2007
- Preferential Use of CXCR4 by R5X4 Human Immunodeficiency Virus Type 1 Isolates for Infection of Primary LymphocytesJournal of Virology, 2005
- Susceptibility of HIV Type 1 to the Fusion Inhibitor T‐20 Is Reduced on Insertion of Host Intercellular Adhesion Molecule 1 in the Virus MembraneThe Journal of Infectious Diseases, 2004
- Sensitivity of HIV Type 1 Subtype C Isolates to the Entry Inhibitor T-20AIDS Research and Human Retroviruses, 2004
- In Vivo Evolution of X4 Human Immunodeficiency Virus Type 1 Variants in the Natural Course of Infection Coincides with Decreasing Sensitivity to CXCR4 AntagonistsJournal of Virology, 2004
- Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytesNature Reviews Drug Discovery, 2004
- Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian–Human Immunodeficiency Virus InfectionThe Journal of Experimental Medicine, 2003
- Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivoJournal of Clinical Investigation, 1999
- Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). Monocyte-tropic and lymphocyte-tropic strains of HIV-1 show distinctive patterns of replication in a panel of cell types.The Journal of Experimental Medicine, 1989